UNSPSC 51322902: Boxidine

This classification denotes an anti-lipidemic agent with the molecular formula C19H20F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8MJ40K4117, chemically known as pyrrolidine, 1-(2-((4-(trifluoromethyl)(1,1-biphenyl)-4-yl)oxy)ethyl)- but generally known as boxidine, which bears US NIH Compound Identifier 31742. Boxidine most often comes in base and hydrochloride forms. European Medicines Agency schedules Boxidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05879MIG.

UNSPSC 51322902 Boxidine, a Commodity code, describes pharmaceutical ingredients and finished medications procured by state and local health agencies, fire departments, and multistate cooperative purchasing alliances. State and local governments buy emergency medications, generic pharmaceuticals, and over-the-counter products under this code—typically through sealed-bid and RFP processes targeting municipal fire and rescue services, state health and human services departments, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. The issuing bodies include individual city purchasing departments, state health commissions, and multistate consortia such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Vendors supply finished pharmaceutical products with specific National Drug Codes (NDCs), packaging configurations, and expiration-date requirements, and must maintain compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), FDA standards, OSHA Hazard Communication Standards, and Section 508 accessibility requirements.

Recent activity spans Florida, Minnesota, Oregon, and Texas. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue, requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a bid deadline of April 8, 2026, and an estimated contract value of $40,000. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to explore vendor capability for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting strategies and cost management models. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and contract terms of two years.